Nivolumab with chemo for pediatric large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding nivolumab (an immunotherapy drug) to a standard chemotherapy regimen for children with primary mediastinal large B-cell lymphoma. It may help improve outcomes for newly diagnosed patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between birth and 17 years old.
- You have been diagnosed with primary mediastinal large B-cell lymphoma, confirmed by lab tests.
- You have not yet received any specific treatment for this lymphoma.
- You or your guardian has signed an informed consent form.
- You are not allergic or intolerant to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.